AR083957A1 - Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica - Google Patents
Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologicaInfo
- Publication number
- AR083957A1 AR083957A1 ARP110104349A ARP110104349A AR083957A1 AR 083957 A1 AR083957 A1 AR 083957A1 AR P110104349 A ARP110104349 A AR P110104349A AR P110104349 A ARP110104349 A AR P110104349A AR 083957 A1 AR083957 A1 AR 083957A1
- Authority
- AR
- Argentina
- Prior art keywords
- nkcir
- individual
- compound
- cells
- treatment
- Prior art date
Links
- 230000002489 hematologic effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 206010066476 Haematological malignancy Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 108091008043 NK cell inhibitory receptors Proteins 0.000 abstract 1
- 229940123591 Natural killer cell inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006994 Precancerous Conditions Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41597310P | 2010-11-22 | 2010-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083957A1 true AR083957A1 (es) | 2013-04-10 |
Family
ID=46146390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104349A AR083957A1 (es) | 2010-11-22 | 2011-11-22 | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9844593B2 (OSRAM) |
| EP (1) | EP2643350A4 (OSRAM) |
| JP (2) | JP6224457B2 (OSRAM) |
| CN (2) | CN106963947A (OSRAM) |
| AR (1) | AR083957A1 (OSRAM) |
| BR (1) | BR112013012138B1 (OSRAM) |
| CA (1) | CA2818684C (OSRAM) |
| EA (1) | EA035033B1 (OSRAM) |
| MX (1) | MX355483B (OSRAM) |
| TW (1) | TWI664191B (OSRAM) |
| WO (1) | WO2012071411A2 (OSRAM) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| US20090196850A1 (en) * | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| EA036545B1 (ru) * | 2011-05-25 | 2020-11-20 | Иннейт Фарма, С.А. | Анти-kir антитела для лечения воспалительных заболеваний |
| US11471486B2 (en) | 2012-09-04 | 2022-10-18 | Inven2 As | Selective and controlled expansion of educated NK cells |
| US20150290316A1 (en) | 2012-10-02 | 2015-10-15 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| EA031025B1 (ru) | 2012-12-21 | 2018-11-30 | Сиэтл Дженетикс, Инк. | Антитела против ntb-a и связанные с ними композиции и способы |
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| EP2992020B1 (en) * | 2013-05-03 | 2020-01-15 | Ohio State Innovation Foundation | Cs1-specific chimeric antigen receptor engineered immune effector cells |
| EP3066128B1 (en) | 2013-11-06 | 2018-10-31 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| WO2015195555A1 (en) * | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| EP3258967A4 (en) | 2015-02-20 | 2018-10-03 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| RU2571551C1 (ru) * | 2015-04-16 | 2015-12-20 | Закрытое акционерное общество "ПЕПТЕК" | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором |
| ES2813580T3 (es) | 2015-04-17 | 2021-03-24 | Bristol Myers Squibb Co | Composiciones que comprenden una combinación de ipilimumab y nivolumab |
| EP3461337A1 (en) | 2015-05-06 | 2019-04-03 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| CN107849148B (zh) | 2015-05-21 | 2023-09-19 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| AU2016299166B2 (en) | 2015-07-24 | 2022-03-31 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| CA3004530A1 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| PL3458053T3 (pl) | 2016-05-20 | 2022-04-25 | Biohaven Therapeutics Ltd. | Stosowanie riluzolu, proleków riluzolu lub analogów riluzolu z immunoterapiami w leczeniu nowotworów |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| JP7542946B2 (ja) | 2016-09-27 | 2024-09-02 | ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム | マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法 |
| IL322445A (en) | 2016-10-12 | 2025-09-01 | Univ Texas | Methods and compounds for tusc2 immunotherapy |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| EP3579879A4 (en) * | 2017-02-09 | 2020-12-16 | Memorial Sloan Kettering Cancer Center | ANTI-BODY ANTI-KIR3DL1 |
| SG11201908337VA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| SG10202110594UA (en) | 2017-03-31 | 2021-11-29 | Bristol Myers Squibb Co | Methods of treating tumor |
| CN113896792B (zh) | 2017-05-12 | 2025-08-22 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| KR102425983B1 (ko) | 2017-10-13 | 2022-07-29 | 하푼 테라퓨틱스, 인크. | 삼중특이적 단백질 및 사용 방법 |
| EP3694884A1 (en) | 2017-10-15 | 2020-08-19 | Bristol-Myers Squibb Company | Methods of treating tumor |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| EP3773685A1 (en) | 2018-03-25 | 2021-02-17 | SNIPR Biome ApS. | Treating & preventing microbial infections |
| WO2019191676A1 (en) | 2018-03-30 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of treating tumor |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019195769A1 (en) * | 2018-04-06 | 2019-10-10 | The Brigham And Women's Hospital, Inc. | Methods of diagnosing and treating aggressive cutaneous t-cell lymphomas |
| CN108728527B (zh) * | 2018-06-06 | 2020-06-09 | 青岛泱深生物医药有限公司 | Hcst基因作为诊治子痫前期的靶标 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| KR102839381B1 (ko) | 2018-08-29 | 2025-07-28 | 내셔널 유니버시티 오브 싱가포르 | 유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| IL281683B2 (en) | 2018-09-25 | 2023-04-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
| MX2021007271A (es) | 2018-12-21 | 2021-07-15 | Onxeo | Nuevas moleculas de acido nucleico conjugado y sus usos. |
| KR102210455B1 (ko) * | 2019-02-28 | 2021-02-02 | 사회복지법인 삼성생명공익재단 | 자연살해세포 활성 검출용 미세입자 및 이를 이용한 검출 방법 |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| CN111973739B (zh) * | 2019-05-23 | 2024-02-13 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| CN114222761B (zh) * | 2020-07-14 | 2024-02-20 | 浙江道尔生物科技有限公司 | 一种抗cld18a2的单域抗体 |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| EP4247940A4 (en) * | 2020-11-18 | 2025-01-01 | The Regents of the University of California | REMOVAL OF MONOCLONAL ANTIBODIES AGAINST NATURAL KILLER CELLS |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| WO2022169825A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| EP4376885A4 (en) * | 2021-07-28 | 2025-07-02 | Merck Sharp & Dohme Llc | METHODS OF TREATING ACUTE MYELOID LEUKEMIA WITH ANTI-ILT3 ANTIBODIES |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| CN118660964A (zh) | 2021-12-16 | 2024-09-17 | 瓦莱里奥治疗公司 | 新型缀合核酸分子及其用途 |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| JP2025518785A (ja) | 2022-06-02 | 2025-06-19 | ブリストル－マイヤーズ スクイブ カンパニー | 抗体組成物及びその使用方法 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| CN1668296A (zh) * | 2002-05-17 | 2005-09-14 | 细胞基因公司 | 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物 |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| KR20060079180A (ko) | 2003-07-02 | 2006-07-05 | 노보 노르디스크 에이/에스 | Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법 |
| CN1852924A (zh) * | 2003-07-02 | 2006-10-25 | 依奈特制药公司 | Pan－kir2dl nk－受体的抗体及其在诊断及治疗中的应用 |
| US7803376B2 (en) * | 2003-07-24 | 2010-09-28 | Innate Pharma S.A. | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| WO2006003179A2 (en) * | 2004-07-01 | 2006-01-12 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
| US20090196850A1 (en) * | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| EP1836225B1 (en) * | 2005-01-06 | 2011-11-02 | Novo Nordisk A/S | Kir-binding agents and methods of use thereof |
| ES2579768T3 (es) | 2007-01-11 | 2016-08-16 | Novo Nordisk A/S | Anticuerpos anti-KIR, formulaciones y usos de los mismos |
| US20100099084A1 (en) | 2008-10-17 | 2010-04-22 | Maher Albitar | Detection of npm1 nucleic acid in acellular body fluids |
-
2011
- 2011-11-22 BR BR112013012138-6A patent/BR112013012138B1/pt not_active IP Right Cessation
- 2011-11-22 EA EA201390756A patent/EA035033B1/ru not_active IP Right Cessation
- 2011-11-22 CN CN201710194545.4A patent/CN106963947A/zh active Pending
- 2011-11-22 WO PCT/US2011/061840 patent/WO2012071411A2/en not_active Ceased
- 2011-11-22 CA CA2818684A patent/CA2818684C/en active Active
- 2011-11-22 AR ARP110104349A patent/AR083957A1/es unknown
- 2011-11-22 MX MX2013005673A patent/MX355483B/es active IP Right Grant
- 2011-11-22 JP JP2013541022A patent/JP6224457B2/ja not_active Expired - Fee Related
- 2011-11-22 US US13/988,954 patent/US9844593B2/en active Active
- 2011-11-22 EP EP11843281.4A patent/EP2643350A4/en not_active Ceased
- 2011-11-22 CN CN2011800622682A patent/CN103298831A/zh active Pending
- 2011-11-22 TW TW100142827A patent/TWI664191B/zh active
-
2016
- 2016-05-12 JP JP2016095779A patent/JP2016199549A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6224457B2 (ja) | 2017-11-01 |
| WO2012071411A2 (en) | 2012-05-31 |
| EP2643350A4 (en) | 2015-01-07 |
| CA2818684A1 (en) | 2012-05-31 |
| US20130251711A1 (en) | 2013-09-26 |
| JP2016199549A (ja) | 2016-12-01 |
| MX2013005673A (es) | 2013-12-06 |
| CN103298831A (zh) | 2013-09-11 |
| EP2643350A2 (en) | 2013-10-02 |
| WO2012071411A3 (en) | 2012-08-16 |
| EA035033B1 (ru) | 2020-04-20 |
| BR112013012138B1 (pt) | 2022-02-22 |
| US9844593B2 (en) | 2017-12-19 |
| CA2818684C (en) | 2023-02-21 |
| BR112013012138A2 (pt) | 2020-09-01 |
| CN106963947A (zh) | 2017-07-21 |
| TW201305210A (zh) | 2013-02-01 |
| EA201390756A1 (ru) | 2014-11-28 |
| JP2014501729A (ja) | 2014-01-23 |
| TWI664191B (zh) | 2019-07-01 |
| MX355483B (es) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
| CL2023002682A1 (es) | Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos | |
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| MX384721B (es) | Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf. | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| EA201491008A1 (ru) | Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита | |
| CO6341486A2 (es) | Tratamiento y profilaxis de amiloidosis | |
| CR20110115A (es) | Metodos para tratar la talasemia | |
| PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
| AR054566A1 (es) | Tratamientoombinado de los tumores que expresan el her | |
| EP4512480A3 (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| EA200970542A1 (ru) | ИНГИБИТОРЫ ДЕЙСТВИЯ Akt | |
| EA201490814A1 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| MY162514A (en) | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors | |
| NZ597031A (en) | Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm) | |
| CO6630082A2 (es) | Tratamiento de lupus nefritis usando laquinimod | |
| EA201690745A1 (ru) | Способы лечения и предотвращения болезни "трансплантат против хозяина" | |
| CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| MX2021013815A (es) | Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer. | |
| CL2009000803A1 (es) | Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada | |
| CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
| MX2008013017A (es) | Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl. | |
| CY1121973T1 (el) | Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |